CoolTan Arts believes mental wellbeing is enhanced by the power of creativity
Join CoolTan Arts for an evening with Julie McNamara.
Book your tickets now for her brilliant new one-woman show!
Let Me Stay is a celebration of life and love as seen through the eyes of Shirley McNamara, Queen of the Mersey.
Thursday, April 3, 6.45pm – 8.30pm at CoolTan Arts, Third Floor, 224-236 Walworth Road, London SE17 1JE.
Running time: 70 minutes. Doors open at 6.45pm for a 7pm start. Refreshments available.
There will be a Q&A after the show. BSL Interpretation and Audio Description provided. Step-free access to the show.
Alzheimer’s does not have to be a tragic and apologetic withdrawal from life. Think of it as a shedding of all care, with two fingers at the world and a constant sense of glee. It’s a lifestyle choice for some…
A tender and unique exploration of Alzheimer’s on family relations. Julie has recorded her mother’s songs and stories, filmed and photographed over many years.
The result is a compelling piece of theatre, an extraordinary love letter sent straight from the heart, welded with a wicked sense of humour.
Tickets are priced on a sliding scale:
- £5 Participants/Volunteers at CoolTan Arts, Unwaged
- £10 Waged
- £15+ High Waged
A percentage of the proceeds go to CoolTan Arts.
To purchase your tickets either:
- Pay online here using PayPal, just enter the ticket price of £5, £10 or £15. You will receive an email confirmation of payment, which you will need to show on the door.
- Email firstname.lastname@example.org or call 020 7701 2696 to reserve tickets. Advance payments by cash or cheque required to confirm booking.
We look forward to seeing you there!
It is World Alzheimer’s Day today – 21st September 2013.
An audio blog by Matthew to remind us what an important day it is. Great blog about events happening around the world today and for the whole of September (World Alzheimer’s Month). Useful links to websites for extra information.
Chance discovery of link between acne drug and psychosis may unlock secrets of mental illness.
A cheap antibiotic normally prescribed to teenagers for acne is to be tested as a treatment to alleviate the symptoms of psychosis in patients with schizophrenia, in a trial that could advance scientific understanding of the causes of mental illness.
The National Institute for Health Research is funding a £1.9m trial of minocycline, which will begin recruiting patients in the UK next month. The research follows case reports from Japan in which the drug was prescribed to patients with schizophrenia who had infections and led to dramatic improvements in their psychotic symptoms.
The chance observation caused researchers to test the drug in patients with schizophrenia around the world. Trials in Israel, Pakistan and Brazil have shown significant improvement in patients treated with the drug.
Scientists believe that schizophrenia and other mental illnesses including depression and Alzheimer’s disease may result from inflammatory processes in the brain. Minocycline has anti-inflammatory and neuroprotective effects which they believe could account for the positive findings.
Details of the trial were presented to the independent Schizophrenia Commission by Bill Deakin, professor of psychiatry at the University of Manchester, who is the lead investigator. The 12-member commission, set up by the mental health charity Rethink, is looking into the treatment and care of people with schizophrenia, and is due to report in the summer.
The first account of minocycline’s effects appeared in 2007 when a 23-year-old Japanese man was admitted to hospital suffering from persecutory delusions and paranoid ideas. He had no previous psychiatric history but became agitated and suffered auditory hallucinations, anxiety and insomnia.
Blood tests and brain scans showed no abnormality and he was started on the powerful anti-psychotic drug halperidol. The treatment had no effect and he was still suffering from psychotic symptoms a week later when he developed severe pneumonia.
He was prescribed minocycline to treat the pneumonia and within two weeks the infection was cleared and the psychosis resolved. Minocycline was stopped and his psychiatric symptoms worsened. Treatment with the drug was resumed and within three days he was better again. Halperidol was reduced but he remained on minocycline. Two years after his psychotic episode, he was still well.
The UK trial aims to recruit 175 patients recently diagnosed with schizophrenia, half of whom will be randomly allocated to take minocycline with their standard anti-psychotic treatment while the remainder take a placebo.
Brain scans will be carried out at the start and end of the 12 month trial to compare loss of grey matter – an effect of schizophrenia – in the two groups. Tests will also measure inflammatory markers in the blood.
Professor Sir Robin Murray, chair of the Schizophrenia Commission said: “Infection or inflammation might be involved in a minority of people with acute psychosis and minocycline might counter this. In depression inflammatory markers go up and in Alzheimer’s too.”